Firm

Analyst

H.C. Wainwright & Co.

  • MS1819 Milestone and Royalty Rights Acquired; Reiterate Buy
  • Phase 2 Protocol in EPI With Cystic Fibrosis Receives TDN Approval; Reiterate Buy
  • FDA Accepts Phase 2 IND in EPI Patients With Cystic Fibrosis; Reiterate Buy
  • Experienced Chief Medical Officer Appointed; Reiterate Buy
  • Powering Past Pancreatic Insufficiency: Initiating at Buy

Raghuram Selvaraju, Ph.D.
Yi Chen, Ph.D.

LifeSci Capital

Jacques A. Villefranc, Ph.D.

Oppenheimer & Co., Inc.

  • Captures a Piece of Potential Future Value; Reiterate Outperform
  • Cystic Fibrosis Foundation Gets Onboard
  • Initiating with Outperform

Leland Gershell, MD, Ph.D.

Trickle Research

David Lavigne

Zacks

John D. Vandermosten

AzurRx BioPharma, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding AzurRx BioPharma, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of AzurRx BioPharma, Inc. or its management. AzurRx BioPharma, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.